GeoVax Labs Inc. (GOVX)
GOVX trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 10-K (us-gaap:RevenueFromContractWithCustomerIncludingAssessedTax), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/832489/000143774926012377/0001437749-26-012377-index.htm. Net income: SEC 10-K (us-gaap:NetIncomeLoss), fiscal year ended 2025-12-31.
Profile
| Field | Value |
|---|---|
| Ticker | GOVX on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | United States |
| IPO year | Not reported by the screener |
| SEC CIK | 0000832489 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | DE |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $2.5M |
| Net income | -$21.5M |
| Operating income | -$21.6M |
| Net margin | -862.3% |
| Operating margin | -869.3% |
| Revenue growth | -37.1% |
| Cash | $3.1M |
| Total assets | $6.3M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 0.4× |
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | States substantial doubt about continuing as a going concern. "These factors collectively raise substantial doubt about the Company's ability to continue as a going concern." | 10-Q 2026-11-12 |
| Cash and burn | $2.2M cash; operating cash flow -$4.1M a quarter. | Report 2026-09-30 |
| Shares outstanding | 544,453 (2026-11-12); 29,705,360 a year earlier; 26,695,287 three years earlier. 1y figure adjusted for splits (1-for-600 overall); 3y figure adjusted for splits (1-for-9000 overall). | Cover page 2026-11-12 |
| Reverse splits, 3 years | 3; latest 1-for-24 on 2026-11-11 | Source 2026-11-11 |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 2 424B5 takedowns, 2 at the market | Latest 2026-02-17 |
| Exchange deficiency notices, 12 months | 2 (8-K item 3.01) | 8-K 2026-08-28 |
| Delisting | 25-NSE filed | 25-NSE 2025-09-29 |
| Auditor | Wipfli LLP, Atlanta, Georgia, United States | PCAOB Form AP 2026-04-21 |
| Late filings, 12 months | 1 NT notice | NT 10-K 2026-03-31 |
| Insider trades, 12 months | Bought $6K, sold $0 on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Quarterly results
| Quarter | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| Q3 2026 2026-09-30 | $0 | -$4.2M | -$4.3M | $2.2M | No debt tags | $0 | 10-Q 2026-11-12 |
| Q2 2026 2026-06-30 | $0 | -$4.4M | -$3.7M | $3.1M | No debt tags | $0 | 10-Q 2026-07-27 |
| Q1 2026 2026-03-31 | $0 | -$5.3M | -$3.5M | $1.3M | No debt tags | $852K | 10-Q 2026-05-14 |
| Q4 2025 2025-12-31 | $0 | -$4.4M | -$5.0M | $3.1M | No debt tags | $2.5M | 10-K 2026-04-15 |
| Q3 2025 2025-09-30 | $0 | -$6.3M | -$6.2M | $5.0M | No debt tags | $3.4M | 10-Q 2026-11-12 |
| Q2 2025 2025-06-30 | $852K | -$5.4M | -$4.3M | $3.1M | No debt tags | $6.1M | 10-Q 2026-07-27 |
| Q1 2025 2025-03-31 | $1.6M | -$5.4M | -$6.0M | $7.4M | No debt tags | $5.6M | 10-Q 2026-05-14 |
| Q4 2024 2024-12-31 | $864K | -$8.3M | -$7.8M | $5.5M | No debt tags | $4.0M | 10-K 2026-04-15 |
From SEC XBRL company facts. Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM S-1 | S-1 | 2026-11-04 |
| Latest annual report FORM 10-K | 10-K | 2026-04-15 |
| Latest quarterly / interim FORM 10-Q | 10-Q | 2026-11-12 |
| Latest current report FORM 8-K | 8-K | 2026-11-12 |
| Latest proxy FORM DEF 14A | DEF 14A | 2026-09-10 |
Source: SEC EDGAR submissions feed, 1,001 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -55.0% |
| 1 month | -73.3% |
| 3 months | -90.1% |
| Year to date | -98.3% |
| 1 year | -99.4% |
| From 52-week high | -99.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| BDRX | Biodexa Pharmaceuticals plc American Depositary Shs | $2.24 | -6.28% | $1.2M |
| MTNB | Matinas Biopharma Holdings Inc. | $0.9270 | +3.00% | $908K |
| ELAB | PMGC Holdings Inc. | $1.66 | +5.06% | $1.3M |
| OGEN | Oragenics Inc. | $0.1980 | -1.49% | $893K |
| KAPA | Kairos Pharma Ltd. | $0.4069 | -10.30% | $1.4M |
| APVO | Aptevo Therapeutics Inc. | $0.5486 | -7.66% | $1.5M |
| SPRC | SciSparc Ltd. | $0.3307 | -10.62% | $815K |
| ARTL | Artelo Biosciences Inc. | $1.70 | -17.87% | $1.6M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier